Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elias Reichel

Uveitis and Ocular Inflammatory Disease Boston, MA Medical Doctor

NPI 1053376939 CMS profile 274866

260 Tremont Street, Bwd 10, Boston, MA 02116

Open in the dashboard

General payments

$673,648

168 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$276,195 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Elias Reichel of Boston, MA is reported in the CMS Open Payments database as having received $673,648 across 168 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $276,195 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $234 1
2024 General $127,945 4
2023 General $213,535 6
2022 General $118,819 21
2021 General $30,355 14
2020 General $68,581 36
2019 General $114,179 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elias Reichel
  • Uveitis and Ocular Inflammatory Disease median
  • Middle half of Uveitis and Ocular Inflammatory Disease
  • National median

In program year 2025, general payments to Elias Reichel were reported at $234. Among 42 Uveitis and Ocular Inflammatory Disease profiles paid that year, the median was $471 and the middle half received between $198 and $5,376.

Show as a table
Year Elias Reichel Uveitis and Ocular Inflammatory Disease median Middle half National median
2019 $114,179 $403 $156–$5,734 $163
2020 $68,581 $164 $99–$6,393 $114
2021 $30,355 $240 $102–$2,572 $132
2022 $118,819 $503 $154–$5,143 $149
2023 $213,535 $655 $222–$5,436 $160
2024 $127,945 $567 $227–$2,571 $164
2025 $234 $471 $198–$5,376 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Thea Pharma Inc. $440,199 11 payments
  2. Regeneron Healthcare Solutions, Inc. $184,382 105 payments
  3. Spark Therapeutics, Inc. $15,941 12 payments
  4. Janssen Research & Development, LLC $12,658 5 payments
  5. EyePoint Pharmaceuticals US, Inc. $5,797 3 payments
  6. Novartis Pharmaceuticals Corporation $5,470 7 payments
  7. F. Hoffmann-La Roche AG $2,702 2 payments
  8. Bausch & Lomb, a division of Bausch Health US, LLC $1,703 3 payments
  9. Cardinal Health 108, LLC $1,575 1 payment
  10. ThromboGenics, Inc. $1,250 1 payment
  11. Other $1,971 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $440,199 11 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $160,851 37 payments
  3. Consulting Fee $56,025 17 payments
  4. Travel and Lodging $12,093 39 payments
  5. Food and Beverage $4,445 62 payments
  6. Education $35 2 payments
Products named General payments · program years 2019–2025
  1. AKTEN $440,199 11 payments
  2. EYLEA $184,382 105 payments
  3. LUXTURNA $15,918 11 payments
  4. BEOVU $5,274 3 payments
  5. YUTIQ $3,022 2 payments
  6. EYP-1901 $2,775 1 payment
  7. Lucentis $2,720 4 payments
  8. VISUDYNE $1,703 3 payments
  9. Jetrea $1,250 1 payment
  10. DEXTENZA $796 2 payments
  11. Other $1,377 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

168 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Uveitis and Ocular Inflammatory Disease in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record